Nouscom
OverviewSuggest Edit
Nouscom develops a technology platform that is based on tumor targeted oncolytic viruses and patient-specific cancer vaccines. The Company offers Endovax antigenless vaccine that encodes immunomodulators, breaks tolerance, and primes/rescues cancer-specific immune response; and Exovax personalized vaccine that encodes neoantigens and boosts cancer-specific responses for sustained immunity. Its technology is based on viral vectors and oncolytic viruses.
| Type | Private | |
| Founded | 2015 | |
| HQ | Basel, CH | Map |
| Website | nouscom.com |
Recent NewsAll News
- Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability
- Nouscom Strengthens Its Management Team
- Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
- Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors
Latest Updates
| Employees (est.) (Sept 2020) | 24 | (+5%) |
| Cybersecurity rating | A | More |
Key People/Management at Nouscom
Riccardo Cortese
Co-Founder
Marina Udier
Chief Executive Officer
Stefano Colloca
Chief Technical Officer and Co-Founder
Tiffany Muller
VP Finance
Alfredo Nicosia
Co-Founder, Advisor
Cinzia Traboni
Senior Director of Regulatory Affairs and Co-Founder
Nouscom Office Locations
Nouscom has offices in Basel and Roma
Basel, CH (HQ)
18 Bäumleingasse
Roma, IT
100 Via di Castel Romano
Nouscom Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Nouscom total Funding | $62.6 m |
Nouscom latest funding size | $49 m |
Time since last funding | 3 years ago |
Nouscom investors | Versant Ventures, 5AM Ventures, Abingworth, LSP BioVentures, LSP |
Nouscom's latest funding round in November 2017 was reported to be $49 m. In total, Nouscom has raised $62.6 m
Nouscom Cybersecurity Score
Nouscom Online and Social Media Presence
Nouscom's Trends
Nouscom News and Updates
July 22, 2020
Nouscom highlights cutting-edge science that led to the design of NOUS-209, a potential off-the-shelf neoantigen cancer vaccine for tumors with Microsatellite Instability
BASEL, Switzerland, July 22, 2020 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the publication of new research describing the cutting-edge science and rationale for the design of NOUS-209 and...
February 26, 2020
Nouscom Strengthens Its Management Team
BASEL, Switzerland, Feb. 26, 2020 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that it has appointed Marina Udier, PhD, as Chief Executive Officer (CEO) and Patricia Delaite, MD, as Chief Medical...
December 09, 2019
Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumors
BASEL, Switzerland, Dec. 9, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating its lead candidate, NOUS-209. In this...
June 03, 2019
Nouscom - IND for NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors
BASEL, Switzerland, June 3, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug (IND) application for the first clinical trial of its lead candidate NOUS-209 has...
November 05, 2018
Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director
BASEL, Switzerland, November 5, 2018 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its proprietary technology platform, announced today that it has appointed John F. McDonald as an...
Nouscom Blogs
November 08, 2018
Nouscom will present at the NeoAg Summit 2018
The 3rd NeoAg Summit is the leading end-to-end industry- focused meeting dedicated to advancing neoantigen-based cancer vaccines and cell therapies. Download the full program of NeoAg Summit 2018.
L'articolo Nouscom will present at the NeoAg Summit 2018 proviene da Nouscom.
October 23, 2018
Nouscom will present at the World Vaccine Congress Europe 2018
Find out the full program here: https://www.terrapinn.com/conference/world-vaccine-congress-europe/agenda.stm
L'articolo Nouscom will present at the World Vaccine Congress Europe 2018 proviene da Nouscom.
May 29, 2018
Nouscom Appoints Adrian Woolfson, M.D., Ph.D as Chief Medical Officer
BASEL, Switzerland – 29th May 2018 Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines based on its clinically validated Exovax platform, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO). …
Nouscom Frequently Asked Questions
When was Nouscom founded?
Nouscom was founded in 2015.
Who are Nouscom key executives?
Nouscom's key executives are Riccardo Cortese, Marina Udier and Stefano Colloca.
How many employees does Nouscom have?
Nouscom has 24 employees.
Who are Nouscom competitors?
Competitors of Nouscom include Orchard Therapeutics, Stealth BioTherapeutics and Affinia Therapeutics.
Where is Nouscom headquarters?
Nouscom headquarters is located at 18 Bäumleingasse, Basel.
Where are Nouscom offices?
Nouscom has offices in Basel and Roma.
How many offices does Nouscom have?
Nouscom has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies